vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 17.0%, a 79.4% gap on every dollar of revenue. On growth, PRA GROUP INC posted the faster year-over-year revenue change (13.7% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 14.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
ACAD vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $333.4M |
| Net Profit | $273.6M | $56.5M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 37.7% |
| Net Margin | 96.3% | 17.0% |
| Revenue YoY | 9.4% | 13.7% |
| Net Profit YoY | 90.3% | 206.3% |
| EPS (diluted) | $1.61 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $333.4M | ||
| Q3 25 | $278.6M | $311.1M | ||
| Q2 25 | $264.6M | $287.7M | ||
| Q1 25 | $244.3M | $269.6M | ||
| Q4 24 | $259.6M | $293.2M | ||
| Q3 24 | $250.4M | $281.5M | ||
| Q2 24 | $242.0M | $284.2M | ||
| Q1 24 | $205.8M | $255.6M |
| Q4 25 | $273.6M | $56.5M | ||
| Q3 25 | $71.8M | $-407.7M | ||
| Q2 25 | $26.7M | $42.4M | ||
| Q1 25 | $19.0M | $3.7M | ||
| Q4 24 | $143.7M | $18.5M | ||
| Q3 24 | $32.8M | $27.2M | ||
| Q2 24 | $33.4M | $21.5M | ||
| Q1 24 | $16.6M | $3.5M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 37.7% | ||
| Q3 25 | 12.8% | -101.4% | ||
| Q2 25 | 12.2% | 29.6% | ||
| Q1 25 | 7.9% | 27.7% | ||
| Q4 24 | 59.1% | 32.1% | ||
| Q3 24 | 12.6% | 32.0% | ||
| Q2 24 | 12.6% | 31.4% | ||
| Q1 24 | 7.4% | 26.0% |
| Q4 25 | 96.3% | 17.0% | ||
| Q3 25 | 25.8% | -131.0% | ||
| Q2 25 | 10.1% | 14.7% | ||
| Q1 25 | 7.8% | 1.4% | ||
| Q4 24 | 55.4% | 6.3% | ||
| Q3 24 | 13.1% | 9.6% | ||
| Q2 24 | 13.8% | 7.6% | ||
| Q1 24 | 8.0% | 1.4% |
| Q4 25 | $1.61 | $1.47 | ||
| Q3 25 | $0.42 | $-10.43 | ||
| Q2 25 | $0.16 | $1.08 | ||
| Q1 25 | $0.11 | $0.09 | ||
| Q4 24 | $0.86 | $0.47 | ||
| Q3 24 | $0.20 | $0.69 | ||
| Q2 24 | $0.20 | $0.54 | ||
| Q1 24 | $0.10 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $104.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $979.9M |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $104.4M | ||
| Q3 25 | $258.0M | $107.5M | ||
| Q2 25 | $253.6M | $131.6M | ||
| Q1 25 | $217.7M | $128.7M | ||
| Q4 24 | $319.6M | $105.9M | ||
| Q3 24 | $155.1M | $141.1M | ||
| Q2 24 | $177.1M | $118.9M | ||
| Q1 24 | $204.7M | $108.1M |
| Q4 25 | $1.2B | $979.9M | ||
| Q3 25 | $917.3M | $928.5M | ||
| Q2 25 | $822.4M | $1.3B | ||
| Q1 25 | $765.2M | $1.2B | ||
| Q4 24 | $732.8M | $1.1B | ||
| Q3 24 | $577.2M | $1.2B | ||
| Q2 24 | $516.7M | $1.1B | ||
| Q1 24 | $464.0M | $1.1B |
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.2B | $5.4B | ||
| Q1 25 | $1.1B | $5.1B | ||
| Q4 24 | $1.2B | $4.9B | ||
| Q3 24 | $976.9M | $4.9B | ||
| Q2 24 | $914.1M | $4.7B | ||
| Q1 24 | $855.1M | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-85.5M |
| Free Cash FlowOCF − Capex | — | $-90.4M |
| FCF MarginFCF / Revenue | — | -27.1% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | -0.18× | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $-85.5M | ||
| Q3 25 | $74.3M | $-10.1M | ||
| Q2 25 | $64.0M | $-12.9M | ||
| Q1 25 | $20.3M | $-52.6M | ||
| Q4 24 | $40.4M | $-94.6M | ||
| Q3 24 | $63.2M | $-35.0M | ||
| Q2 24 | $25.0M | $-29.5M | ||
| Q1 24 | $29.1M | $-73.0M |
| Q4 25 | — | $-90.4M | ||
| Q3 25 | $73.9M | $-11.3M | ||
| Q2 25 | — | $-14.2M | ||
| Q1 25 | — | $-53.5M | ||
| Q4 24 | — | $-98.6M | ||
| Q3 24 | $63.2M | $-36.1M | ||
| Q2 24 | — | $-30.8M | ||
| Q1 24 | — | $-73.5M |
| Q4 25 | — | -27.1% | ||
| Q3 25 | 26.5% | -3.6% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | — | -33.6% | ||
| Q3 24 | 25.2% | -12.8% | ||
| Q2 24 | — | -10.8% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 0.1% | 0.4% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | -0.18× | -1.51× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | -0.30× | ||
| Q1 25 | 1.07× | -14.37× | ||
| Q4 24 | 0.28× | -5.13× | ||
| Q3 24 | 1.93× | -1.29× | ||
| Q2 24 | 0.75× | -1.37× | ||
| Q1 24 | 1.76× | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
